Asset
AMPRELOXETINE
THERAVANCE BIOPHARMA INC. ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01458340 | phase2 | completed | 2011-12-01 | 2013-10-01 | Theravance Biopharma | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| NCT03750552 | phase3 | completed | 2019-01-24 | 2021-07-21 | Theravance Biopharma | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure |
| NCT03432793 | phase1 | completed | 2018-02-28 | 2018-04-21 | Theravance Biopharma | Drug-Drug Interaction (DDI) Study for TD-9855 |
| NCT04200573 | phase1 | completed | 2020-01-13 | 2021-08-19 | Theravance Biopharma | Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 |
| NCT03829657 | phase3 | terminated | 2019-02-22 | 2021-11-10 | Theravance Biopharma | Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure |
FDA applications (0)
This company has no applications containing this asset.